# Journal of Clinical Psychiatry

## Subject Index to Volume 50: January 1989 Through December 1989


**Acquired Immunodeficiency Syndrome**
Anxiety and stigmatizing aspects of HIV infection. Fullilove, Nov Suppl 5–8
Anxiety and the neuropsychiatry of AIDS. Fernandez, Nov Suppl 9–14
Treatable causes of CNS dysfunction in AIDS patients (letter). Levenson; Ostrow reply, Apr 147–148

**Adolescents**
ECT in children and adolescents (letter). McGough; Guttmacher reply, Mar 106–107

**Adrenocorticotropic Hormone**
Clinical significance of psychoneuroendocrinology in psychiatry: Focus on the thyroid and adrenal. Nemeroff, May Suppl 13–20

**Affective Disorders see also Bipolar Disorder; Depression; Mania**
Current concepts in affective disorders (Festschrift). Keller, May 157–162
Diagnosis of affective disorders and schizophrenia in the U.S.: A 1984 survey of psychiatrists and graduating residents. Jampala, June 212–216
Introduction: Emerging perspectives on valproate in affective disorders. Post, Mar Suppl 3–9
Meaning of serum lithium levels in maintenance therapy of mood disorders: A review of the literature. Gelenberg, Dec Suppl 17–22
Valproate use in acute mania and bipolar disorder: An international perspective. Fawcett, Mar Suppl 10–12

**Aggression**
Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. Ratey, Oct 382–384

**Agoraphobia**
Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. Noyes, May 163–169

**Agranulocytosis**
Clozapine for refractory schizophrenia: An open study of 14 patients treated up to 2 years. Mattes, Oct 389–391
Clozapine: Guidelines for clinical management. Lieberman, Sept 329–338

**AIDS-Related Complex**
Psychostimulant response in AIDS-related complex patients. Holmes, Jan 5–8

**Akathisia**
Fluoxetine-induced akathisia: Clinical and theoretical implications. Lipinski, Sept 339–342

**Alcoholism**
Alcohol withdrawal: A review of clinical management. Castaneda, Aug 278–284
Anxiety and alcoholism. Linnoila, Nov Suppl 26–29
Coexisting obsessive compulsive disorder and alcoholism. Eisen, Mar 96–98
Coexisting panic disorder and alcoholism (letter). Burant; Nunes reply, May 187–188
Prospects for a rational pharmacotherapy of alcoholism (Festschrift). Meyer, Nov 403–412
Tricyclic antidepressants in the treatment of alcoholism and drug abuse. Weiss, July Suppl 4–9

**Alprazolam**
Alprazolam treatment of avoidant personality traits in social phobic patients. Reich, Mar 91–95
Avoidant personality traits in social phobic patients treated with alprazolam (letter). Rajadhyaksha; Reich reply, Nov 437
Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. Charney, Nov 418–423

**Amantadine**
Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. Rego, Apr 143–144

**Anorexia Nervosa**
Gastric outlet obstruction masquerading as anorexia nervosa. Lee, May 184–185

**Anticholinergic Agents**
Euphorigenic properties of anticholinergics (letter). Knable, May 186

**Anticonvulsants**
Introduction: Emerging perspectives on valproate in affective disorders. Post, Mar Suppl 3–9
Sensitization, kindling, and anticonvulsants in mania. Post, Dec Suppl 23–30
Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: Two cases. Saxon, June 228–229

**Antidepressants see also specific drugs**
Cardiovascular effects and toxicity of anxiolytics and antidepressants. Jefferson, Oct 368–378
Current status of antidepressants: Clinical pharmacology and therapy (Festschrift). Baldessarini, Apr 117–126
Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. Weilburg, Dec 447–449
Long-term continuation antidepressant treatment: A comparison study. Aronson, Aug 285–289
Major depression in renal dialysis patients: An open trial of antidepressant therapy. Kennedy, Feb 60–63; Correction, Apr 148
Summary: Clinical challenges in depression. Gelenberg, July Suppl 47–48

**Antidepressants, Tricyclic**
Depression, heart disease, and tricyclic antidepressants. Roose, July Suppl 12–16
Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. Downs, June 226–227
Introduction: New perspectives on the use of tricyclic antidepressants. Gelenberg, July Suppl 3
Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. Noyes, May 163–169
Tricyclic antidepressants for medically ill geriatric patients. Small, July Suppl 27–31
Tricyclic antidepressants in the treatment of alcoholism and drug abuse. Weiss, July Suppl 4–9
Tricyclic antidepressants in the treatment of poststroke depression. Fedoroff, July Suppl 18–23
Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. Preskorn, July Suppl 34–42
Tricyclics: Adequate trials and plasma levels (letter). Piper; Khan reply, Jan 36

**Antipsychotic Agents see also specific drugs**
Comparison of two adjunctive treatment strategies in acute mania. Busch, Dec 453–455
Current status of neuroleptic therapy (Festschrift). Kane, Sept 322–328
Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Rosebush, Aug 295–298; Correction, Dec 472

**Anxiety**
Anxiety and alcoholism. Linnoila, Nov Suppl 26–29
Anxiety and cancer: The patient and the family. Holland, Nov Suppl 20–25
Anxiety and coronary heart disease in midlife. Rahe, Nov Suppl 36–39
Anxiety and physical illness in the elderly. Turnbull, Nov Suppl 40–45
Anxiety and stigmatizing aspects of HIV infection. Fullilove, Nov Suppl 5–8
Anxiety and the neuropsychiatry of AIDS. Fernandez, Nov Suppl 9–14
Anxiety disorders and the use and abuse of drugs. Roth, Nov Suppl 30–35
Family anxiety after traumatic events. Terr, Nov Suppl 15–19
Introduction. Anxiety: The silent partner. Pasnau, Nov Suppl 3–4
Separation anxiety and fear or avoidance of flying (letter). Schneck, Dec 474
Valproate in anxiety and withdrawal syndromes. Roy-Byrne, Mar Suppl 44–48

**Anxiolytics see also specific drugs**
Cardiovascular effects and toxicity of anxiolytics and antidepressants. Jefferson, Oct 368–378

**Behavior**
Non-erotic self-choking in five psychiatric inpatients. Colón, Dec 465–468
Psychobiological effects of carbohydrates. Spring, May Suppl 27–33

**Benzodiazepines see also specific drugs**
Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. Charney, Nov 418–423
Comparison of two adjunctive treatment strategies in acute mania. Busch, Dec 453–455

**Biologic Markers**
Biologic markers in borderline personality disorder: A review. Lahmeyer, June 217–225
Chlorprothixene-induced hypouricemia: A biologic indicator of drug compliance. Shalev, Nov 424–427
Inability to predict postdexamethasone cortisol levels by serum sodium levels. Levy, Jan 16–17
Neuroendocrine markers in periodic catatonia (letter). McCall, Mar 109

**Bipolar Disorder**
Adjuncts and alternatives to lithium therapy for bipolar affective disorder. Sachs, Dec Suppl 31–39
Introduction: Emerging perspectives on valproate in affective disorders. Post, Mar Suppl 3–9
Long-term use of valproate in primary psychiatric disorders. Hayes, Mar Suppl 35–39
Phenomenology of rapid cycling manic depression and its treatment with valproate. Calabrese, Mar Suppl 30–34

U.S. experience with valproate in manic depressive illness: A multicenter trial. Brown, Mar Suppl 13–16
Use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. Sovner, Mar Suppl 40–43
Valproate in psychiatric disorders: Literature review and clinical guidelines. McElroy, Mar Suppl 23–29
Valproate use in acute mania and bipolar disorder: An international perspective. Fawcett, Mar Suppl 10–12

**Blood Levels**
Plasma trimipramine levels (letter). Boyer; Simpson reply, Mar 108–109
Tricyclics: Adequate trials and plasma levels (letter). Piper; Khan reply, Jan 36

**Books Reviewed**
Ablon J: *Living With Difference: Families With Dwarf Children.* Thaggard, Dec 478
Altschul AM (ed): *Weight Control: A Guide for Counselors and Therapists.* Larocca, Jan 38–39
Bachrach LL, Nadelson CC (eds): *Treating Chronically Mentally Ill Women.* Surawicz, Mar 112
Barnard GW, Fuller AK, Robbins L, Shaw T: *The Child Molester: An Integrated Approach to Evaluation and Treatment.* Baumbach, Aug 313
Benson HB: *The Dying Child: An Annotated Bibliography.* Weller and Fristad, June 233
Berg R, Franzen M, Wedding D: *Screening for Brain Impairment: A Manual for Mental Health Practice.* Ross and Long, May 189–190
Bernstein NR, Breslau AJ, Graham JA (eds): *Coping Strategies for Burn Survivors and Their Families.* Kuhn, Nov 439
Blatner A, Blatner A: *Foundations of Psychodrama: History, Theory and Practice.* Surawicz, June 234
Boaz JT: *Delivering Mental Health Care: A Guide for HMOs.* Muñoz, Mar 110
Chess S, Thomas A, Hertzig M (eds): *Annual Progress in Child Psychiatry and Child Development: 1987.* Schmid, Sept 359
Cohen RL, Dulcan MK (eds): *Basic Handbook of Training in Child and Adolescent Psychiatry.* Heston, Mar 111
Diamond S: *Hope for Your Headache Problem.* Walker, June 234
Editorial Committee of the Chicago Institute for Psychoanalysis: *The Annual Review of Psychoanalysis, Vol. 15.* Rinsley, Jan 39
Freedman DX, Lourie RS, Meltzer HY, Talbott JA, Weiner H (eds): *1988: The Year Book of Psychiatry and Applied Mental Health.* Leon-Andrade, Mar 112
Friedman RC: *Male Homosexuality: A Contemporary Psychoanalytic Perspective.* Levine, Apr 149
Gooddy W: *Time and the Nervous System.* Waziri, Nov 438–439
Green SA, Goldberg RL, Goldstein DM, Leibenluft E: *Limit Setting in Clinical Practice.* Rosenbluth, July 271
Guidano V: *Complexity of the Self: A Developmental Approach to Psychopathology and Therapy.* Pallanti Aug 313
Hamilton NG: *Self and Others: Object Relations Theory in Practice.* Huntley, Dec 477–478
Hatfield AB, Lefly HP (eds): *Families of the Mentally Ill: Coping and Adaption.* Deal, Aug 311
Jespersen E, Pegg PF: *Using Psychosocial Counselling Techniques in Primary Health Care.* Brodaty, June 234
Katschnig H (ed): *Life Events and Psychiatric Disorders: Controversial Issues.* Links, Aug 312
Klarreich SH (ed): *Health and Fitness in the Workplace: Health Education in Business Organizations.* Rice, Mar 111
Liberman RP (ed): *Psychiatric Rehabilitation of Chronic Mental Patients.* Walker, Feb 75
Lion JR, Adler WN, Webb WL Jr (eds): *Modern Hospital Psychiatry.* Katz, Feb 74
Lubin B, Lubin AW: *Comprehensive Index of Group Psychotherapy Writings.* Khanna, May 190
Luborsky L, Crits-Christoph P, Mintz J, Auerbach A: *Who Will Benefit From Psychotherapy? Predicting Therapeutic Outcomes.* Schuyler, Sept 360–361
Martin JB, Reichlin S: *Clinical Neuroendocrinology, 2nd Ed.* Extein, Mar 112
McRoy RG, Grotevant HD, Zurcher LA Jr: *Emotional Disturbance in Adopted Adolescents.* King, Sept 359–360
Mendelson WB: *Human Sleep: Research and Clinical Care.* Neylan and Reynolds, Oct 394–395
Moffic HS, Silverman SW, Adams GL (eds): *Psychiatry: A Problem-Oriented Approach.* Pál, Mar 111
Nace EP: *The Treatment of Alcoholism.* Strassman, Feb 74–75
Perris C: *Cognitive Therapy With Schizophrenic Patients.* Goldstein, Dec 477
Putman FW: *Diagnosis and Treatment of Multiple Personality Disorder.* Goldstein Nov 438
Rachman S, Maser J: *Panic: Psychological Perspectives.* Mavissakalian, May 189
Reid WH: *The Treatment of Psychiatric Disorders: Revised for the DSM-III-R.* Larocca, Oct 395
Roccatagliata G: *A History of Ancient Psychiatry.* Larocca, Feb 75
Rogers R (ed): *Clinical Assessment of Malingering and Deception.* Gold, June 233
Rothblum ED, Cole E (eds): *Treating Women's Fear of Failure.* Surawicz, Sept 361
Schepank H: *Epidemiology of Psychogenic Disorders: The Mannheim Study: Results of a Field Survey in the Federal Republic of Germany.* Pepple and Tsuang, May 190
Schetky DH, Green AH: *Child Sexual Abuse: A Handbook for Health Care and Legal Professionals.* Heston, Sept 360
Schneiderman L: *The Literary Mind: Portraits in Pain and Creativity.* Rinsley, Apr 150
Selvini M: *The Work of Mara Selvini Palazzoli.* Tondo, Aug 311
Steinberg D: *Basic Adolescent Psychiatry.* Bernet, Sept 359
Stierlin H, Weber G: *Unlocking the Family Door: A Systemic Approach to the Understanding and Treatment of Anorexia Nervosa.* Larocca Nov 439
Tabar JI (ed): *Compulsive Gambling.* Jones, Oct 394
Tarter R, van Thiel DH, Edwards KL (eds): *Medical Neuropsychology: The Impact of Disease on Behavior.* Cavanaugh and Gilmer, Apr 149–150
Theodore WH (ed): *Clinical Neuroimaging.* Nasrallah, Mar 110
Tischler GL (ed): *Diagnosis and Classification in Psychiatry: A Critical Appraisal of DSM-III.* Alarcon, Jan 38
Turner JT (ed): *Handbook of Hospital Security and Safety.* Bornstein, Aug 312–313
Walsh BT (ed): *Eating Behaviors in Eating Disorders.* Larocca, Sept 361
Walsh BW, Rosen PM: *Self-Mutilation: Theory, Research and Treatment.* Freeman, Oct 395
Wolf ME, Mosnaim AD (eds): *Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects.* Kane, Oct 394

**Borderline Personality Disorder**
Biologic markers in borderline personality disorder: A review. Lahmeyer, June 217–225
Prevalence and clinical characteristics of borderline patients in an eating-disordered population. Johnson, Jan 9–15

**Brain**
Brain, depression, and the immune system. Restak, May Suppl 23–25

**Brain Mapping**
Clinical use of topographic brain electrical activity mapping in psychiatry. Garber, June 205–211

**Bulimia**
Childhood sexual abuse in women with bulimia. Bulik, Dec 460–464
Comorbidity of bulimia nervosa and personality disorder. Yates, Feb 57–59
Therapeutic effectiveness of bupropion for bulimia: A possible artifact (letter). Hahn, May 188

**Bupropion**
Bupropion dosing recommendations (letter). Ionescu-Pioggia, Oct 392
Seizures and bupropion: A review. Davidson, July 256–261
Therapeutic effectiveness of bupropion for bulimia: A possible artifact (letter). Hahn, May 188

**Buspirone**
Buspirone and transvestic fetishism (letter). Fishbain; Fedoroff reply, Nov 436–437
Buspirone revisited (letter). Lydiard, Aug 308
Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. Ratey, Oct 382–384

**Cancer**
Anxiety and cancer: The patient and the family. Holland, Nov Suppl 20–25

**Capgras Syndrome**
Capgras syndrome and minor head trauma (letter). Fishbain; Bienenfeld reply, Dec 474–475
Capgras syndrome following minor head trauma. Bienenfeld, Feb 68–69

**Carbamazepine**
Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment (letter). Arana, Sept 356–357

**Carbohydrates**
Psychobiological effects of carbohydrates. Spring, May Suppl 27–33

**Case Reporting**
Sample bias and overinference: Two sources of error in interpreting case report data (letter). Coffman, Mar 105

**Catatonia**
Neuroendocrine markers in periodic catatonia (letter). McCall, Mar 109

**Child Abuse, Sexual**
Childhood sexual abuse in women with bulimia. Bulik, Dec 460–464
Long-term effects of sibling incest. Daie, Nov 428–431

**Children**
ECT in children and adolescents (letter). McGough; Guttmacher reply, Mar 106–107

**Clonazepam**
Clonazepam in the treatment of obsessive compulsive disorder associated with panic disorder in one patient. Bodkin, July 265–266

**Clozapine**
Clozapine for refractory schizophrenia: An open study of 14 patients treated up to 2 years. Mattes, Oct 389–391
Clozapine: Guidelines for clinical management. Lieberman, Sept 329–338

**Cocaine**
Homicidal psychosis during the combined use of cocaine and an over-the-counter cold preparation (letter). Strauss, Apr 147
Hyperthyroidism in a cocaine-dependent patient. Burton, Aug 305–306
More on cocaine addiction and Dr. William S. Halsted (letter). Wright; Schneck reply, Sept 358

**Comorbidity**
Comorbidity of bulimia nervosa and personality disorder. Yates, Feb 57–59

**Compliance**
Chlorprothixene-induced hypouricemia: A biologic indicator of drug compliance. Shalev, Nov 424–427
Maintenance lithium treatment: Side effects and compliance. Gitlin, Apr 127–131

**Computed Tomography**
SPECT scan reveals abnormality in somatization disorder patient (letter). Lazarus, Dec 475–476

**Continuation Treatment see also Maintenance Treatment**
Adequate treatment with imipramine in continuation treatment. Kupfer, July 250–255
Long-term continuation antidepressant treatment: A comparison study. Aronson, Aug 285–289

**Corrections**
Major depression in renal dialysis patients: An open trial of antidepressant therapy. Kennedy, Feb 60–63; Correction, Apr 148
New frontiers in psychotherapy (Festschrift). Karasu, Feb 46–52; Correction, Apr 148
Plagiarism: Editor's comment. Gelenberg, Feb 72

Psychiatric diagnoses in patients who have chronic fatigue syndrome. Kruesi, Feb 53–56; Correction, Apr 148
Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Rosebush, Aug 295–298; Correction, Dec 472

**Corticotropin Releasing Factor**
Clinical significance of psychoneuroendocrinology in psychiatry: Focus on the thyroid and adrenal. Nemeroff, May Suppl 13–20

**Cortisol**
Inability to predict postdexamethasone cortisol levels by serum sodium levels. Levy, Jan 16–17

**Depression**
Brain, depression, and the immune system. Restak, May Suppl 23–25
Clinical significance of psychoneuroendocrinology in psychiatry: Focus on the thyroid and adrenal. Nemeroff, May Suppl 13–20
Comparative trial of fluoxetine versus trazodone in outpatients with major depression. Perry, Aug 290–294
Depression as a manifestation of obstructive sleep apnea: Reversal with nasal continuous positive airway pressure. Millman, Sept 348–351
Depression, heart disease, and tricyclic antidepressants. Roose, July Suppl 12–16
Hallervorden-Spatz disease in a psychiatric setting. Morphy, Feb 66–68
Inability to predict postdexamethasone cortisol levels by serum sodium levels. Levy, Jan 16–17
Long-term use of valproate in primary psychiatric disorders. Hayes, Mar Suppl 35–39
Major depression in renal dialysis patients: An open trial of antidepressant therapy. Kennedy, Feb 60–63; Correction, Apr 148
New insights into the nature and heterogeneity of mood disorders. Akiskal, May Suppl 6–10
Overview: Depression in health and illness. Freedman, May Suppl 3–5
Psychotic and nonpsychotic depression: Comparison of response to ECT (letter). Black; Khan reply, May 186
Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment (letter). Arana, Sept 356–357
Stimulants in the treatment of depression: A critical overview. Satel, July 241–249
Stress, depression, and the immune system. Stein, May Suppl 35–40
Summary: Clinical challenges in depression. Gelenberg, July Suppl 47–48
Tolerance to phenelzine and subsequent refractory depression: Three cases. Donaldson, Jan 33–35
Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. Thase, Oct 385–388
Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. Thase, Nov 413–417
Tricyclic antidepressants in the treatment of poststroke depression. Fedoroff, July Suppl 18–23

**Dexamethasone Suppression Test**
Dexamethasone suppression test and response to MAOI treatment (letter). Rihmer, Mar 107–108
Inability to predict postdexamethasone cortisol levels by serum sodium levels. Levy, Jan 16–17
MAOIs in DST nonsuppressors (letter). Liebowitz; Janicak reply, Mar 107

**Dextroamphetamine**
Psychostimulant response in AIDS-related complex patients. Holmes, Jan 5–8

**Diagnosis/Classification**
Psychiatric diagnoses in patients who have chronic fatigue syndrome. Kruesi, Feb 53–56; Correction, Apr 148

**Diagnosis, Differential**
Case of developmental right hemisphere dysfunction: Implications for psychiatric diagnosis and management. Abramson, Feb 70–71
Gastric outlet obstruction masquerading as anorexia nervosa. Lee, May 184–185
Hallervorden-Spatz disease in a psychiatric setting. Morphy, Feb 66–68

**Diazepam**
High-dose diazepam in neuroleptic-resistant schizophrenia with tardive dyskinesia (letter). Eapen, Aug 309

**Dimenhydrinate**
Dimenhydrinate addiction in a schizophrenic woman (letter). Bartlik, Dec 476

**Dose-Response Relationship**
Dose-dependent kinetics of trimipramine (letter). Musa, Aug 307
Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. Preskorn, July Suppl 34–42

**Doxepin**
Case of immune complex hemolytic anemia, thrombocytopenia, and acute renal failure associated with doxepin use. Wolf, Mar 99–100

**Drug Administration Schedule**
Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Newton, Apr 132–135

**Drug Interactions**
Homicidal psychosis during the combined use of cocaine and an over-the-counter cold preparation (letter). Strauss, Apr 147
Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. Downs, June 226–227
Lithium and propranolol: Possible synergism (letter)? Becker, Dec 473
MAOIs and hypertensive crises: The role of OTC drugs. Harrison, Feb 64–65
Neurotoxicity resulting from a combination of lithium and loxapine (letter). Fuller, May 187

**Drug Side Effects**
Aggravation of diabetic nephropathy by lithium: A case report and review of the literature. Pawel, Mar 101–103
Cardiovascular effects and toxicity of anxiolytics and antidepressants. Jefferson, Oct 368–378
Case of immune complex hemolytic anemia, thrombocytopenia, and acute renal failure associated with doxepin use. Wolf, Mar 99–100
Exacerbation of fever by psychotropic drugs in an elderly demented man (letter). Kerr, Sept 357–358
Fluoxetine-induced akathisia: Clinical and theoretical implications. Lipinski, Sept 339–342
Imipramine-related tinnitus (letter). Laird, Apr 146
Jitteriness and panic disorder (letter). Ciccone; Pohl reply, Feb 72–73
Maintenance lithium treatment: Side effects and compliance. Gitlin, Apr 127–131
Managing antidepressant-induced sweating (letter). Butt, Apr 146–147
Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. Rego, Apr 143–144
Naproxen reversal of nortriptyline-induced orthostatic hypotension (letter). Forster, Sept 356
Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease (letter). von Hafften; Stewart reply, June 230–231
Trimipramine and dopamine receptor blockade (letter). Golden, Oct 392–393
Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. Langlow, Apr 144–145

**Drug Therapy**
Anxiety disorders and the use and abuse of drugs. Roth, Nov Suppl 30–35
Current status of antidepressants: Clinical pharmacology and therapy (Festschrift). Baldessarini, Apr 117–126
Prospects for a rational pharmacotherapy of alcoholism (Festschrift). Meyer, Nov 403–412

**Drug Therapy, Combination**
Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. Weilburg, Dec 447–449
Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: A case study. Alessi, Mar 103–104

**Drugs, Nonprescription**
Homicidal psychosis during the combined use of cocaine and an over-the-counter cold preparation (letter). Strauss, Apr 147

**Dyskinesia, Drug-Induced**
Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. Reiter, Jan 26–27
High-dose diazepam in neuroleptic-resistant schizophrenia with tardive dyskinesia (letter). Eapen, Aug 309

**Eating Disorders see also Anorexia Nervosa; Bulimia**
Hyperamylasemia and its relationship to binge-purge episodes: Development of a clinically relevant laboratory test. Gwirtsman, June 196–204
Prevalence and clinical characteristics of borderline patients in an eating-disordered population. Johnson, Jan 9–15
Zinc deficiency and eating disorders. Humphries, Dec 456–459

**Editorials**
Editorial tribute. Gelenberg, Feb 44–45
*Journal of Clinical Psychiatry:* A half century. Gelenberg, Jan 3–4
*Journal of Clinical Psychiatry:* Our second half-century. Gelenberg, Dec 445–446

**Electroconvulsive Therapy**
Are brief pulse and sine wave ECT equally efficient? Fox, Nov 432–435
Concurrent use of lithium and ECT (letter). Adityanjee; DeQuardo reply, Aug 307–308
ECT in children and adolescents (letter). McGough; Guttmacher reply, Mar 106–107
Ergoloid mesylates and ECT. Sachs, Mar 87–90
Poor interrater reliability of MECTA EEG recordings of ECT seizure duration. Guze, Apr 140–142
Psychotic and nonpsychotic depression: Comparison of response to ECT (letter). Black; Khan reply, May 186

**Electroencephalography**
Clinical use of topographic brain electrical activity mapping in psychiatry. Garber, June 205–211
Fear episodes due to limbic seizures with normal ictal scalp EEG: A subdural electrographic study. Devinsky, Jan 28–30
Nasopharyngeal EEG recording in psychiatric patients. Gupta, July 262–264
Poor interrater reliability of MECTA EEG recordings of ECT seizure duration. Guze, Apr 140–142

**Epilepsy**
Scope and use of valproate in epilepsy. Penry, Mar Suppl 17–22

**Epstein-Barr Virus**
Psychiatric diagnoses in patients who have chronic fatigue syndrome. Kruesi, Feb 53–56; Correction, Apr 148

**Ergoloid Mesylates**
Ergoloid mesylates and ECT. Sachs, Mar 87–90

**Evoked Potentials**
Clinical use of topographic brain electrical activity mapping in psychiatry. Garber, June 205–211

**Family**
Anxiety and cancer: The patient and the family. Holland, Nov Suppl 20–25
Family anxiety after traumatic events. Terr, Nov Suppl 15–19

**Fatigue**
Psychiatric diagnoses in patients who have chronic fatigue syndrome. Kruesi, Feb 53–56; Correction, Apr 148
Psychobiological effects of carbohydrates. Spring, May Suppl 27–33

**Fenfluramine**
Treatment of seasonal depression with *d*-fenfluramine. O'Rourke, Sept 343–347

**Fluoxetine**
Comparative trial of fluoxetine versus trazodone in outpatients with major depression. Perry, Aug 290–294
Fluoxetine added to non-MAOI antidepressants con-

verts nonresponders to responders: A preliminary report. Weilburg, Dec 447–449
Fluoxetine treatment of obsessive compulsive disorder (letter). Granet, Nov 436
Fluoxetine-induced akathisia: Clinical and theoretical implications. Lipinski, Sept 339–342
Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. Downs, June 226–227
Premenstrual syndrome treatments (letter). Jacobson; Harrison reply, Oct 393
Treatment of premenstrual depression with nortriptyline: A pilot study. Harrison, Apr 136–139
**Forensic Psychiatry**
Mary Harris PMS trial (letter). Kaye, Aug 308–309
**Freons**
Death by Freon (letter). Goldsmith, Jan 36–37
**Genetics**
Hallervorden-Spatz disease in a psychiatric setting. Morphy, Feb 66–68
Recent developments in genetics of manic-depressive illness. Gershon, Dec Suppl 4–7
**Geriatric Patients**
Anxiety and physical illness in the elderly. Turnbull, Nov Suppl 40–45
Exacerbation of fever by psychotropic drugs in an elderly demented man (letter). Kerr, Sept 357–358
Tricyclic antidepressants for medically ill geriatric patients. Small, July Suppl 27–31
**Gilles de la Tourette's Disease**
Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: A case study. Alessi, Mar 103–104
**Hallervorden-Spatz Disease**
Hallervorden-Spatz disease (letter). Miller; Morphy reply, Aug 309
Hallervorden-Spatz disease in a psychiatric setting. Morphy, Feb 66–68
**Haloperidol**
Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Newton, Apr 132–135
Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: A case study. Alessi, Mar 103–104
**Halsted, William S.**
More on cocaine addiction and Dr. William S. Halsted (letter). Wright; Schneck reply, Sept 358
**Head Injury**
Capgras syndrome and minor head trauma (letter). Fishbain; Bienenfeld reply, Dec 474–475
Capgras syndrome following minor head trauma. Bienenfeld, Feb 68–69
**Heart Diseases**
Anxiety and coronary heart disease in midlife. Rahe, Nov Suppl 36–39
Depression, heart disease, and tricyclic antidepressants. Roose, July Suppl 12–16
**Huntington's Disease**
Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease (letter). von Hafften; Stewart reply, June 230–231
**Hyperamylasemia**
Hyperamylasemia and its relationship to binge-purge episodes: Development of a clinically relevant laboratory test. Gwirtsman, June 196–204
**Hyperprolactinemia**
Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. Rego, Apr 143–144
**Hypertension**
MAOIs and hypertensive crises: The role of OTC drugs. Harrison. Feb 64–65
**Hyperthyroidism**
Hyperthyroidism in a cocaine-dependent patient. Burton, Aug 305–306
**Hypotension**
Naproxen reversal of nortriptyline-induced orthostatic hypotension (letter). Forster, Sept 356
**Hypouricemia**
Chlorprothixene-induced hypouricemia: A biologic indicator of drug compliance. Shalev, Nov 424–427
**Imipramine**
Adequate treatment with imipramine in continuation treatment. Kupfer, July 250–255
Imipramine-related tinnitus (letter). Laird, Apr 146
**Immune System**
Behavioral and neural influences on cellular immune responses: Effects of stress and interleukin-1. Weiss, May Suppl 43–53
Brain, depression, and the immune system. Restak, May Suppl 23–25
Stress, depression, and the immune system. Stein, May Suppl 35–40
**Interleukin**
Behavioral and neural influences on cellular immune responses: Effects of stress and interleukin-1. Weiss, May Suppl 43–54
***Journal of Clinical Psychiatry***
Editorial tribute. Gelenberg, Feb 44–45
*Journal of Clinical Psychiatry:* A half century (editorial). Gelenberg, Jan 3–4
*Journal of Clinical Psychiatry:* Our second half-century (editorial). Gelenberg, Dec 445–446
**Koro**
Case of koro in a refugee family: Association with depression and folie à deux. Westermeyer, May 181–183
**Lithium**
Adjuncts and alternatives to lithium therapy for bipolar affective disorder. Sachs, Dec Suppl 31–39
Aggravation of diabetic nephropathy by lithium: A case report and review of the literature. Pawel, Mar 101–103
Concurrent use of lithium and ECT (letter). Adityanjee; DeQuardo reply, Aug 307–308
Effectiveness of lithium in schizophrenia: Do we really have an answer? Atre-Vaidya, May 170–173
Lithium and propranolol: Possible synergism (letter)? Becker, Dec 473
Lithium: A therapeutic magic wand (Festschrift). Jefferson, Mar 81–86
Maintenance lithium treatment: Side effects and compliance. Gitlin, Apr 127–131
Meaning of serum lithium levels in maintenance therapy of mood disorders: A review of the literature. Gelenberg, Dec Suppl 17–22
Neurotoxicity resulting from a combination of lithium and loxapine (letter). Fuller, May 187
Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment (letter). Arana, Sept 356–357
Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. Thase, Nov 413–417
**Logic**
Sample bias and overinference: Two sources of error in interpreting case report data (letter). Coffman, Mar 105
**Lorazepam**
Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. Charney, Nov 418–423
**Loxapine**
Neurotoxicity resulting from a combination of lithium and loxapine (letter). Fuller, May 187
**Maintenance Treatment see also Continuation Treatment**
Maintenance lithium treatment: Side effects and compliance. Gitlin, Apr 127–131
Meaning of serum lithium levels in maintenance therapy of mood disorders: A review of the literature. Gelenberg, Dec Suppl 17–22
**Mania**
Biology of recurrence: New directions for the pharmacologic bridge. Goodwin, Dec Suppl 40–44
Comparison of two adjunctive treatment strategies in acute mania. Busch, Dec 453–455
Introduction. Mania: Important new findings. Rosenbaum, Dec Suppl 3
Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. Rego, Apr 143–144
Phenomenology of rapid cycling manic depression and its treatment with valproate. Calabrese, Mar Suppl 30–34
Recent developments in genetics of manic-depressive illness. Gershon, Dec Suppl 4–7
Sensitization, kindling, and anticonvulsants in mania. Post, Dec Suppl 23–30
Sleep loss: A preventable cause of mania and other excited states. Wehr, Dec Suppl 8–16
Summary. Rosenbaum, Dec Suppl 45–47
U.S. experience with valproate in manic depressive illness: A multicenter trial. Brown, Mar Suppl 13–16
Valproate in psychiatric disorders: Literature review and clinical guidelines. McElroy, Mar Suppl 23–29
Valproate use in acute mania and bipolar disorder: An international perspective. Fawcett, Mar Suppl 10–12
**Marfan syndrome**
Delusions in Marfan syndrome (letter). van Bavel, Dec 473–474
**Memory**
Ergoloid mesylates and ECT. Sachs, Mar 87–90
**Mental Retardation**
Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. Ratey, Oct 382–384
Use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. Sovner, Mar Suppl 40–43
**Methadone**
Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: Two cases. Saxon, June 228–229
**Methodology**
New frontiers in psychotherapy (Festschrift). Karasu, Feb 48–52; Correction, Apr 148
**Methylphenidate**
Psychostimulant response in AIDS-related complex patients. Holmes, Jan 5–8
**Molindone**
Relation of serum molindone levels to serum prolactin levels and antipsychotic response. Pandurangi, Oct 379–381
**Monoamine Oxidase Inhibitors**
Dexamethasone suppression test and response to MAOI treatment (letter). Rihmer, Mar 107–108
MAOIs and hypertensive crises: The role of OTC drugs. Harrison, Feb 64–65
MAOIs in DST nonsuppressors (letter). Liebowitz; Janicak reply, Mar 107
**Mortality**
Mortality from neuroleptic malignant syndrome. Shalev, Jan 18–25
**Munchausen Syndrome**
Munchausen syndrome: New cause for concern (letter). Connelly, Feb 73
**Naproxen**
Naproxen reversal of nortriptyline-induced orthostatic hypotension (letter). Forster, Sept 356
**Nephrosis**
Aggravation of diabetic nephropathy by lithium: A case report and review of the literature. Pawel, Mar 101–103
**Neuroleptic Malignant Syndrome**
Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. Keck, Sept 352–355
Mortality from neuroleptic malignant syndrome. Shalev, Jan 18–25
Patients with neuroleptic malignant syndrome histories: What happens when they are rehospitalized? Gelenberg, May 178–180
Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. Langlow, Apr 144–145
Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Rosebush, Aug 295–298; Correction, Dec 472
**Neurologic Disorders**
Case of developmental right hemisphere dysfunction: Implications for psychiatric diagnosis and management. Abramson, Feb 70–71

**Nicotine**
Nicotine gum use with nicotine addiction (letter). Resnick, Aug 310

**Nifedipine**
Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: A case study. Alessi, Mar 103–104

**Nortriptyline**
Naproxen reversal of nortriptyline-induced orthostatic hypotension (letter). Forster, Sept 356
Premenstrual syndrome treatments (letter). Feder; Harrison reply, Oct 393
Treatment of premenstrual depression with nortriptyline: A pilot study. Harrison, Apr 136–139

**Obsessive Compulsive Disorder**
Catatonic signs in severe obsessive compulsive disorder. Hermesh, Aug 303–305
Clonazepam in the treatment of obsessive compulsive disorder associated with panic disorder in one patient. Bodkin, July 265–266
Coexisting obsessive compulsive disorder and alcoholism. Eisen, Mar 96–98
Fluoxetine treatment of obsessive compulsive disorder (letter). Granet, Nov 436
Normal and disordered compulsivity: Evidence against a continuum. Pitman, Dec 450–452
Obsessive compulsive disorder (letter). Ciccone, June 231
Obsessive compulsive disorder (letter). Price, June 231–232
Obsessive compulsive disorder (letter). Thweatt, June 232
Obsessive compulsive disorder (letter). Warneke, June 232

**Panic**
Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. Charney, Nov 418–423
Clonazepam in the treatment of obsessive compulsive disorder associated with panic disorder in one patient. Bodkin, July 265–266
Coexisting panic disorder and alcoholism (letter). Burant; Nunes reply, May 187–188
Fear episodes due to limbic seizures with normal ictal scalp EEG: A subdural electrographic study. Devinksy, Jan 28–30
Jitteriness and panic disorder (letter). Ciccone; Pohl reply, Feb 72–73
Panic attack-associated placental abruption: A case report. Cohen, July 266–267
Panic disorder in the medically ill. Katon, Aug 299–302
Postpartum anxiety disorder (letter). Bybee; Metz reply, July 268–269
Postpartum anxiety disorder (letter). Fisch; Metz reply, July 268–269
Postpartum anxiety disorder (letter). Kraus; Metz reply, July 268–269
Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. Noyes, May 163–169
Serum potassium levels in panic disorder patients (letter). Kim; Kemperman reply, July 269–270

**Personality Disorders see also Borderline Personality Disorder**
Alprazolam treatment of avoidant personality traits in social phobic patients. Reich, Mar 91–95
Comorbidity of bulimia nervosa and personality disorder. Yates, Feb 57–59
Paranoia about paranoid personality research (letter). Thompson-Pope, Aug 310

**Pharmacology**
Biology of recurrence: New directions for the pharmacologic bridge. Goodwin, Dec Suppl 40–44
Current status of antidepressants: Clinical pharmacology and therapy (Festschrift). Baldessarini, Apr 117–126

**Phenelzine**
Tolerance to phenelzine and subsequent refractory depression: Three cases. Donaldson, Jan 33–35

**Phobic Disorders**
Alprazolam treatment of avoidant personality traits in social phobic patients. Reich, Mar 91–95
Avoidant personality traits in social phobic patients treated with alprazolam (letter). Rajadhyaksha; Reich reply, Nov 437
Separation anxiety and fear or avoidance of flying (letter). Schneck, Dec 474

**Physical Illness**
Anxiety and physical illness in the elderly. Turnbull, Nov Suppl 40–45

**Pindolol**
Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease (letter). von Hafften; Stewart reply, June 230–231

**Polydipsia**
Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. Langlow, Apr 144–145

**Pregnancy**
Panic attack-associated placental abruption: A case report. Cohen, July 266–267

**Premenstrual Syndrome**
Mary Harris PMS trial (letter). Kaye, Aug 308–309
Premenstrual syndrome treatments (letter). Feder; Harrison reply, Oct 393
Premenstrual syndrome treatments (letter). Jacobson; Harrison reply, Oct 393
Treatment of premenstrual depression with nortriptyline: A pilot study. Harrison, Apr 136–139

**Prolactin**
Relation of serum molindone levels to serum prolactin levels and antipsychotic response. Pandurangi, Oct 379–381

**Propranolol**
Lithium and propranolol: Possible synergism (letter)? Becker, Dec 473

**Psychostimulants see also specific drugs**
Psychostimulant response in AIDS-related complex patients. Holmes, Jan 5–8

**Psychotherapy**
New frontiers in psychotherapy (Festschrift). Karasu, Feb 46–52; Correction, Apr 148

**Psychotic Disorders**
Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. Reiter, Jan 26–27
Long-term use of valproate in primary psychiatric disorders. Hayes, Mar Suppl 35–39
U.S. experience with valproate in manic depressive illness: A multicenter trial. Brown, Mar Suppl 13–16
Valproate in psychiatric disorders: Literature review and clinical guidelines. McElroy, Mar Suppl 23–29

**Psychotropic Drugs**
Exacerbation of fever by psychotropic drugs in an elderly demented man (letter). Kerr, Sept 357–358

**Renal Dialysis**
Major depression in renal dialysis patients: An open trial of antidepressant therapy. Kennedy, Feb 60–63; Correction, Apr 148

**Schizophrenia**
Clozapine for refractory schizophrenia: An open study of 14 patients treated up to 2 years. Mattes, Oct 389–391
Diagnosis of affective disorders and schizophrenia in the U.S.: A 1984 survey of psychiatrists and graduating residents. Jampala, June 212–216
Dimenhydrinate addiction in a schizophrenic woman (letter). Bartlik, Dec 476
Effectiveness of lithium in schizophrenia: Do we really have an answer? Atre-Vaidya, May 170–173
Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Newton, Apr 132–135
Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. Reiter, Jan 26–27
High-dose diazepam in neuroleptic-resistant schizophrenia with tardive dyskinesia (letter). Eapen, Aug 309
Hospitalized schizophrenic patient views about seclusion. Hammill, May 174–177

**Seasonal Affective Disorder**
Seasonal affective disorder and visual impairment. Rosenthal, Dec 469–472
Treatment of seasonal depression with *d*-fenfluramine. O'Rourke, Sept 343–347

**Seclusion**
Hospitalized schizophrenic patient views about seclusion. Hammill, May 174–177

**Seizures**
Fear episodes due to limbic seizures with normal ictal scalp EEG: A subdural electrographic study. Devinsky, Jan 28–30
Seizures and bupropion: A review. Davidson, July 256–261

**Self-Choking**
Non-erotic self-choking in five psychiatric inpatients. Colón, Dec 465–468

**Sexual Abuse**
Childhood sexual abuse in women with bulimia. Bulik, Dec 460–464
Long-term effects of sibling incest. Daie, Nov 428–431

**Sleep**
Sleep loss: A preventable cause of mania and other excited states. Wehr, Dec Suppl 8–16

**Sleep Disorders**
Depression as a manifestation of obstructive sleep apnea: Reversal with nasal continuous positive airway pressure. Millman, Sept 348–351

**Somatization Disorder**
SPECT scan reveals abnormality in somatization disorder patient (letter). Lazarus, Dec 475–476

**Steroids**
Anabolic-androgenic steroid dependence. Brower, Jan 31–33

**Stimulants**
Stimulants in the treatment of depression: A critical overview. Satel, July 241–249

**Stress**
Behavioral and neural influences on cellular immune responses: Effects of stress and interleukin-1. Weiss, May Suppl 43–53
Stress, depression, and the immune system. Stein, May Suppl 35–40

**Substance Abuse**
Anabolic-androgenic steroid dependence. Brower, Jan 31–33
Anxiety disorders and the use and abuse of drugs. Roth, Nov Suppl 30–35
Death by Freon (letter). Goldsmith, Jan 36–37
Dimenhydrinate addiction in a schizophrenic woman (letter). Bartlik, Dec 476
Homicidal psychosis during the combined use of cocaine and an over-the-counter cold preparation (letter). Strauss, Apr 147
Intravenous nasal decongestant use (letter). Edlund, Oct 392
More on cocaine addiction and Dr. William S. Halsted (letter). Wright; Schneck reply, Sept 358
Nicotine gum use with nicotine addiction (letter). Resnick, Aug 310
Tricyclic antidepressants in the treatment of alcoholism and drug abuse. Weiss, July Suppl 4–9

**Substance Withdrawal Syndrome**
Alcohol withdrawal: A review of clinical management. Castaneda, Aug 278–284
Valproate in anxiety and withdrawal syndromes. Roy-Byrne, Mar Suppl 44–48

**Sweating**
Managing antidepressant-induced sweating (letter). Butt, Apr 146–147

**Tardive Dyskinesia see Dyskinesia, Drug-Induced**

**Thyroid Hormones**
Clinical significance of psychoneuroendocrinology in psychiatry: Focus on the thyroid and adrenal. Nemeroff, May Suppl 13–20

**Tinnitus**
Imipramine-related tinnitus (letter). Laird, Apr 146

**Tobacco**
Realities of tobacco addiction (letter). Allen, Apr 148

**Transvestism**
Buspirone and transvestic fetishism (letter). Fishbain; Federoff reply, Nov 436–437

**Trazodone**
Comparative trial of fluoxetine versus trazodone in outpatients with major depression. Perry, Aug 290–294
**Triiodothyronine**
Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. Thase, Oct 385–388
**Trimipramine**
Dose-dependent kinetics of trimipramine (letter). Musa, Aug 307
Plasma trimipramine levels (letter). Boyer; Simpson reply, Mar 108–109
Trimipramine and dopamine receptor blockade (letter). Golden, Oct 392–393
Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. Langlow, Apr 144–145
**Valproate**
Introduction: Emerging perspectives on valproate in affective disorders. Post, Mar Suppl 3–9
Long-term use of valproate in primary psychiatric disorders. Hayes, Mar Suppl 35–39
Phenomenology of rapid cycling manic depression and its treatment with valproate. Calabrese, Mar Suppl 30–34
Scope and use of valproate in epilepsy. Penry, Mar Suppl 17–22
U.S. experience with valproate in manic depressive illness: A multicenter trial. Brown, Mar Suppl 13–16
Use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. Sovner, Mar Suppl 40–43
Valproate in anxiety and withdrawal syndromes. Roy-Byrne, Mar Suppl 44–48
Valproate in psychiatric disorders: Literature review and clinical guidelines. McElroy, Mar Suppl 23–29
Valproate use in acute mania and bipolar disorder: An international perspective. Fawcett, Mar Suppl 10–12
Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: Two cases. Saxon, June 228–229
**Verapamil**
Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. Reiter, Jan 26–27
**Women**
Childhood sexual abuse in women with bulimia. Bulik, Dec 460–464
**Zinc**
Zinc deficiency and eating disorders. Humphries, Dec 456–459

# Journal of Clinical Psychiatry

## Author Index to Volume 50: January 1989 Through December 1989


**Abramson R, Katz DA:** Case of developmental right hemisphere dysfunction: Implications for psychiatric diagnosis and management. Feb 70–71

**Adityanjee:** Concurrent use of lithium and ECT (letter with reply). Aug 307

**Adler L see Reiter S**

**Aizenberg D see Hermesh H**

**Akiskal HS:** New insights into the nature and heterogeneity of mood disorders. May Suppl 6–10

**Akiskal HS see Downs JM**

**Alarcon RD:** Review of Tischler GL (ed): *Diagnosis and Classification in Psychiatry: A Critical Appraisal of DSM-III.* Jan 38

**Alarcon RD see Langlow JR**

**Alessi NE, Walden M, Hsieh PS:** Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: A case study. Mar 103–104

**Allen AD:** Realities of tobacco addiction (letter). Apr 148

**Angrist B see Bartlik B; Reiter S**

**Arana GW, Santos AB, Knox EP, Ballenger JC:** Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment (letter). Sept 356–357

**Arato M see Rihmer Z**

**Aronson TA, Shukla S:** Long-term continuation antidepressant treatment: A comparison study. Aug 285–289

**Atkinson H see Ostrow DG**

**Atre-Vaidya N, Taylor MA:** Effectiveness of lithium in schizophrenia: Do we really have an answer? May 170–173

**Avery DH see Khan A; Khan A**

**Baldessarini RJ:** Current status of antidepressants: Clinical pharmacology and therapy (Festschrift). Apr 117–126

**Ballenger JC see Arana GW**

**Balon R see Kim C-L; Pohl R**

**Bartlik B, Galanter M, Angrist B:** Dimenhydrinate addiction in a schizophrenic woman (letter). Dec 476

**Baudhuin MG see Gelenberg AJ**

**Baumbach J:** Review of Barnard GW, Fuller AK, Robbins L, Shaw T: *The Child Molester: An Integrated Approach to Evaluation and Treatment.* Aug 313

**Baxter LR Jr see Guze BH**

**Becker D:** Lithium and propranolol: Possible synergism (letter)? Dec 473

**Becker KJ see Weiss JM**

**Beersma D see Kemperman CJF**

**Bellinghausen B see Gelenberg AJ; Sachs GS**

**Beresford TP see Brower KJ**

**Bernet W:** Review of Steinberg D: *Basic Adolescent Psychiatry.* Sept 359

**Biederman J see Weilburg JB**

**Bienenfeld D, Brott T:** Reply to Fishbain DA: Capgras syndrome and minor head trauma (letter). Dec 475

**Bienenfeld D, Brott T:** Capgras syndrome following minor head trauma. Feb 68–69

**Birger M see Shalev A**

**Black DW, Winokur G:** Psychotic and nonpsychotic depression: Comparison of response to ECT (letter with reply). May 186

**Blackard WG see Pandurangi AK**

**Blow FC see Brower KJ**

**Bodkin JA, White K:** Clonazepam in the treatment of obsessive compulsive disorder associated with panic disorder in one patient. July 265–266

**Bornstein PE:** Review of Turner JT (ed): *Handbook of Hospital Security and Safety.* Aug 312–313

**Bourgeois MJ see Spring B**

**Bouwens JMP see van Bavel LP**

**Boyer WF, Feighner JP:** Plasma trimipramine levels (letter with reply). Mar 108

**Brass C see Yates WR**

**Brodaty H:** Review of Jespersen E, Pegg PF: *Using Psychosocial Counselling Techniques in Primary Health Care.* June 234

**Brott T see Bienenfeld D; Bienenfeld D**

**Brower KJ, Blow FC, Beresford TP, Fuelling C:** Anabolic-androgenic steroid dependence. Jan 31–33

**Brown R:** U.S. experience with valproate in manic depressive illness: A multicenter trial. Mar Suppl 13–16

**Bulik CM, Sullivan PF, Rorty M:** Childhood sexual abuse in women with bulimia. Dec 460–464

**Burant DM:** Coexisting panic disorder and alcoholism (letter with reply). May 187–188

**Burton KR, Martin CA, Murray FT, Muniz CE:** Hyperthyroidism in a cocaine-dependent patient. Aug 305–306

**Busch FN, Miller FT, Weiden PJ:** Comparison of two adjunctive treatment strategies in acute mania. Dec 453–455

**Butt MM:** Managing antidepressant-induced sweating (letter). Apr 146–147

**Bybee P:** Postpartum anxiety disorder (letter with reply). July 268

**Calabrese JR, Delucchi GA:** Phenomenology of rapid cycling manic depression and its treatment with valproate. Mar Suppl 30–34

**Campbell RJ see Fox HA**

**Cannon DJ see Newton JEO**

**Carlisle CC see Millman RP**

**Carlson B See Colón EA**

**Carosella NW see Gwirtsman HE**

**Carroll JA see Gelenberg AJ**

**Castaneda R, Cushman P:** Alcohol withdrawal: A review of clinical management. Aug 278–284

**Cavanaugh S, Gilmer W:** Review of Tarter R, van Thiel DH, Edwards KL (eds): *Medical Neuropsychology: The Impact of Disease on Behavior.* Apr 149–150

**Chandra P see Eapen V**

**Channabasavanna SM see Eapen V**

**Charlton M see Gupta BK**

**Charney DS, Woods SW:** Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. Nov 418–423

**Chebli R see O'Rourke D**

**Chiodo J see Spring B**

**Chmielinski HE see Ratey JJ**

**Chow CC see Lee S**

**Chung S see Lee S**

**Ciccone PE:** Jitteriness and panic disorder (letter with reply). Feb 72

**Ciccone PE:** Obsessive compulsive disorder (letter). June 231

**Cierpial MA see Weiss JM**

**Cochran SD see Gitlin MJ**

**Coffman JA, Dilsaver SC, Smeltzer DJ, O'Donnell V, Olson SC:** Sample bias and overinference: Two sources of error in interpreting case report data (letter). Mar 105

**Cohen LS, Rosenbaum JF, Heller VL:** Panic attack-associated placental abruption: A case report. July 266–267

**Cohen S see Khan A; Khan A**

**Colón EA, Popkin MK, Carlson B:** Non-erotic self-choking in five psychiatric inpatients. Dec 465–468

**Connelly PJ, Gilmour F:** Munchausen syndrome: New cause for concern (letter). Feb 73

**Conradty M see Wolf B**

**Cook BL see Noyes R Jr; Perry PJ**

**Cotterell KP see Lazarus A**

**Couch L see Newton JEO**

**Craven JL see Kennedy SH**

**Cretella H see Guttmacher LB**

**Crosson AW see Pawel BR**

**Cushman P see Castaneda R**

**Daie N, Witztum E, Eleff M:** Long-term effects of sibling incest. Nov 428–431

**Dalack GW see Roose SP**

**Dale J see Kruesi MJP**

**Davidson J:** Seizures and bupropion: A review. July 256–261

**Davis JM see Janicak PG**

**Deal N:** Review of Hatfield AB, Lefly HP (eds): *Families of the Mentally Ill: Coping and Adaption.* Aug 311

**Deal N see Downs JM**

**Dean JC see Penry JK**

**DellaBella P see Rosenthal NE**

**Delucchi GA see Calabrese JR**

**DeQuardo JR, Tandon R:** Reply to Adityanjee: Concurrent use of lithium and ECT (letter). Aug 307–308

**Devinsky O, Soto S, Theodore WH, Porter RJ:** Fear episodes due to limbic seizures with normal ictal scalp EEG: A subdural electrographic study. Jan 28–30

**Dilsaver SC see Coffman JA**

**Donaldson SR:** Tolerance to phenelzine and subsequent refractory depression: Three cases. Jan 33–35

**Donnelly PJ see Roy-Byrne PP**

**Downs AD see Downs JM**

**Downs JM, Downs AD, Rosenthal TL, Deal N, Akiskal HS:** Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. June 226–227

**Duffy FH see Garber HJ**

**Dunner FJ see Perry PJ**

**Eapen V, Mukherjee D, Chandra P, Sinha V, Khanna S, Channabasavanna SM:** High-dose diazepam in neuroleptic-resistant schizophrenia with tardive dyskinesia (letter). Aug 309

**Edlund M, Grabowski J:** Intravenous nasal decongestant use (letter). Oct 392
**Elsen JL, Rasmussen SA:** Coexisting obsessive compulsive disorder and alcoholism. Mar 96–98
**Eleff M see Dale N**
**Endicott J see Harrison WM**
**Enright A see Johnson C**
**Evans DL see Golden RN**
**Extein IL:** Review of Martin JB, Reichliu S: *Clinical Neuroendocrinology, 2nd Ed.* Mar 112
**Falk WE see Gelenberg AJ; Sachs GS**
**Farhadi AM see Gelenberg AJ; Sachs GS**
**Fawcett J:** Valproate use in acute mania and bipolar disorder: An international perspective. Mar Suppl 10–12
**Feder R:** Premenstrual syndrome treatments (letter with reply). Oct 393
**Federman M see Pawel BR**
**Fedoroff JP:** Reply to Fishbain DA: Buspirone and transvestic fetishism (letter). Nov 437
**Fedoroff JP, Robinson RG:** Tricyclic antidepressants in the treatment of poststroke depression. July Suppl 18–23
**Feighner JP see Boyer, WF**
**Feldman JA see Morphy MA; Morphy MA**
**Fergusen BD see Pawel BR**
**Fernandez F:** Anxiety and the neuropsychiatry of AIDS. Nov Suppl 9–14
**Fernandez F see Holmes VF**
**Fisch RZ:** Postpartum anxiety disorder (letter with reply). July 268–269
**Fishbain DA:** Buspirone and transvestic fetishism (letter with reply). Nov 436–437
**Fishbain DA:** Capgras syndrome and minor head trauma (letter with reply) Dec 474–475
**Fody EP see Newton JEO**
**Fogel BS see Millman RP**
**Forster HS:** Naproxen reversal of nortriptyline-induced orthostatic hypotension (letter). Sept 356
**Fox HA, Rosen A, Campbell RJ:** Are brief pulse and sine wave ECT equally efficient? Nov 432–435
**Frank E see Kupfer DJ; Thase ME**
**Freedman AM:** Overview: Depression in health and illness. May Suppl 3–5
**Freeman AM III:** Review of Walsh BW, Rosen PM: *Self-Mutilation: Theory, Research and Treatment.* Oct 395
**Fristad MA see Weller EB**
**Fuelling C see Brower KJ**
**Fuller MA, Sajatovic M:** Neurotoxicity resulting from a combination of lithium and loxapine (letter). May 187
**Fullilove MT:** Anxiety and stigmatizing aspects of HIV infection. Nov Suppl 5–8
**Galanter M see Bartlik B**
**Garber HJ, Weilburg JB, Duffy FH, Manschreck TC:** Clinical use of topographic brain electrical activity mapping in psychiatry. June 205–211
**Garvey MJ see Noyes R Jr; Perry PJ**
**Gelenberg AJ:** Editorial tribute. Feb 44
**Gelenberg AJ:** Introduction: New perspectives on the use of tricyclic antidepressants. July Suppl 3
**Gelenberg AJ:** *Journal of Clinical Psychiatry:* A half century (editorial). Jan 3–4
**Gelenberg AJ:** *Journal of Clinical Psychiatry:* Our second half-century. Dec 445–446
**Gelenberg AJ:** Plagiarism: Editor's comment. Feb 72
**Gelenberg AJ:** Summary: Clinical challenges in depression. July Suppl 47–48
**Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, Farhadi AM:** Patients with neuroleptic malignant syndrome histories: What happens when they are rehospitalized? May 178–180
**Gelenberg AJ, Carroll JA, Baudhuin MG, Jefferson JW, Greist JH:** Meaning of serum lithium levels in maintenance therapy of mood disorders: A review of the literature. Dec Suppl 17–22
**Gelenberg AJ see Rosebush PI; Sachs GS**
**George DT see Gwirtsman HE**
**Gershon ES:** Recent developments in genetics of manic-depressive illness. Dec Suppl 4–7
**Giller EL Jr see Rego MD**
**Gilmer W see Cavanaugh S**
**Gilmour F see Connelly PJ**
**Gitlin MJ, Cochran SD, Jamison KR:** Maintenance lithium treatment: Side effects and compliance. Apr 127–131
**Glassman AH see Roose SP**
**Gleason R see O'Rourke D**
**Goff DC see Metz A**
**Gold DD Jr:** Review of Rogers R (ed): *Clinical Assessment of Malingering and Deception.* June 233
**Gold ME see Guze BH**
**Golden RN, Miller H, Evans DL:** Trimipramine and dopamine receptor blockade (letter). Oct 392–393
**Goldsmith RJ:** Death by Freon (letter). Jan 36–37
**Goldstein ET:** Review of Perris C: *Cognitive Therapy With Schizophrenic Patients.* Dec 477
**Goldstein ET:** Review of Putman FW: *Diagnosis and Treatment of Multiple Personality Disorder.* Nov 438
**Gombos I see Rihmer Z**
**Goodman WK see Price LH**
**Goodwin FK:** Biology of recurrence: New directions for the pharmacologic bridge. Dec Suppl 40–44
**Grabowski J see Edlund M**
**Granet RB:** Fluoxetine treatment of obsessive compulsive disorder. Nov 436
**Grant I see Ostrow DG**
**Greene RC see Gwirtsman HE**
**Greist JH see Gelenberg AJ**
**Grohmann R see Wolf B**
**Gupta BK, Yerevanian B, Charlton M:** Nasopharyngeal EEG recording in psychiatric patients. July 262–264
**Guttmacher LB, Cretella H, Houghtalen R:** Reply to McGough JJ, McCall WV, Shelp FE: ECT in children and adolescents (letter). Mar 106–107
**Guze BH, Liston EH, Baxter LR Jr, Richelmer SH, Gold ME:** Poor interrater reliability of MECTA EEG recordings of ECT seizure duration. Apr 140–142
**Gwirtsman HE, Kaye WH, George DT, Carosella NW, Greene RC, Jimerson DC:** Hyperamylasemia and its relationship to binge-purge episodes: Development of a clinically relevant laboratory test. June 196–204
**Gyorgy S see Rihmer Z**
**Hada Z see Rihmer Z**
**Hahn L see Rosenthal NE**
**Hahn WK:** Therapeutic effectiveness of bupropion for bulimia: A possible artifact (letter). May 188
**Hammill K, McEvoy JP, Koral H, Schneider N:** Hospitalized schizophrenic patient views about seclusion. May 174–177
**Harden M see Spring B**
**Harrison WM:** Replies to Jacobson JN; Feder R: Premenstrual syndrome treatments (letters). Oct 393
**Harrison WM, Endicott J, Nee J:** Treatment of premenstrual depression with nortriptyline: A pilot study. Apr 136–139
**Harrison WM, McGrath PJ, Stewart JW, Quitkin F:** MAOIs and hypertensive crises: The role of OTC drugs. Feb 64–65
**Hawker CS see Saxon AJ**
**Hayes SG:** Long-term use of valproate in primary psychiatric disorders. Mar Suppl 35–39
**Heller VL see Cohen LS**
**Hermesh H, Hoffnung RA, Aizenberg D, Molcho A, Munitz H:** Catatonic signs in severe obsessive compulsive disorder. Aug 303–305
**Hermesh H see Shalev A; Shalev A**
**Heston J:** Review of Cohen RL, Dulcan MK (eds): *Basic Handbook of Training in Child and Adolescent Psychiatry.* Mar 111
**Heston J:** Review of Schetky DH, Green AH: *Child Sexual Abuse: A Handbook for Health Care and Legal Professionals.* Sept 360
**Hoffnung RA see Hermesh H**
**Holland JC:** Anxiety and cancer: The patient and the family. Nov Suppl 20–25
**Holmes VF, Fernandez F, Levy JK:** Psychostimulant response in AIDS-related complex patients. Jan 5–8
**Houghtalen R see Guttmacher LB**
**Hsieh PS see Alessi NE**
**Hudson JI see McElroy SL**
**Humphries L, Vivian B, Stuart M, McClain CJ:** Zinc deficiency and eating disorders. Dec 456–459
**Huntley M:** Review of Hamilton NG: *Self and Others: Object Relations Theory in Practice.* Dec 477–478
**Ionescu-Pioggia M, Johnston JA:** Bupropion dosing recommendations (letter). Oct 392
**Jacobson JN:** Premenstrual syndrome treatments (letter with reply). Oct 393
**Jamison KR see Gitlin MJ**
**Jampala VC, Sierles FS, Taylor MA:** Diagnosis of affective disorders and schizophrenia in the U.S.: A 1984 survey of psychiatrists and graduating residents. June 212–216
**Janicak PG, Sharma RP, Davis JM:** Reply to Liebowitz MR: MAOIs in DST nonsuppressors (letter). Mar 107
**Jarrett DB see Thase ME; Thase ME**
**Jefferson JW:** Cardiovascular effects and toxicity of anxiolytics and antidepressants. Oct 368–378
**Jefferson JW:** Lithium: A therapeutic magic wand (Festschrift). Mar 81–86
**Jefferson JW see Gelenberg AJ**
**Jenike MA see Pitman RK**
**Jenike M see Sachs GS**
**Jensen CF see von Hafften AH**
**Jimerson DC see Gwirtsman HE**
**Johns CA see Lieberman JA**
**Johnson C, Tobin D, Enright A:** Prevalence and clinical characteristics of borderline patients in an eating-disordered population. Jan 9–15
**Johnston JA see Ionescu-Pioggia M**
**Jones BA:** Review of Tabar JI (ed): *Compulsive Gambling.* Oct 394
**Kane JM:** Current status of neuroleptic therapy (Festschrift). Sept 322–328
**Kane JM:** Review of Wolf ME, Mosnaim AD (eds): *Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects.* Oct 394
**Kane JM see Lieberman JA**
**Karasu TB:** New frontiers in psychotherapy (Festschrift), Feb 46–52. Correction, Apr 148
**Katon W, Roy-Byrne PP:** Panic disorder in the medically ill. Aug 299–302
**Katz DA see Abramson R**
**Katz SE:** Review of Lion JR, Adler WN, Webb WL Jr (eds): *Modern Hospital Psychiatry.* Feb 74
**Kaye NS:** Mary Harris PMS trial (letter). Aug 308–309
**Kaye WA see Pawel BR**
**Kaye WH see Gwirtsman HE**
**Keck PE Jr, Sebastianelli J, Pope HG Jr, McElroy SL:** Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. Sept 352–355
**Keck PE Jr see McElroy SL**
**Keller MB:** Current concepts in affective disorders (Festschrift). May 157–162
**Kelly K see Weilburg JB**
**Kelly MW see Perry PJ**
**Kemperman CJF, Schoorlemmer GHM, van den Hoofdakker R, Koolhaas JM, Beersma D:** Reply to Kim C-L, Yeragani VK, Balon R, Pohl R: Serum potassium levels in panic disorder patients (letter). July 270
**Kennedy SH, Craven JL, Rodin GM:** Major depression in renal dialysis patients: An open trial of antidepressant therapy. Feb 60–63. Correction, Apr 148
**Kerr HD:** Exacerbation of fever by psychotropic drugs in an elderly demented man (letter). Sept 357–358
**Khan A, Solan WJ, Avery DH, Cohen S:** Reply to Black DW, Winokur G: Psychotic and nonpsychotic depression: Comparison of response to ECT (letter). May 186
**Khan A, Solan WJ, Avery DH, Cohen S:** Reply to Piper A Jr: Tricyclics: Adequate trials and plasma levels (letter). Jan 36
**Khan MY see Pawel BR**
**Khanna JL:** Review of Lubin B, Lubin AW: *Comprehensive Index of Group Psychotherapy Writings.* May 190
**Khanna S see Espen V**

**Kilburn G see Morphy MA; Morphy MA**
**Kim C-L, Yeragani VK, Balon R, Pohl R:** Serum potassium levels in panic disorder patients (letter with reply). July 269–270
**King P:** Review of McRoy RG, Grotevant HD, Zurcher LA Jr: *Emotional Disturbance in Adopted Adolescents.* Sept 359–360
**King R see Lahmeyer HW**
**Knable MB:** Euphorigenic properties of anticholinergics (letter). May 186
**Knox EP see Arana GW**
**Koolhaas JM see Kemperman CJF**
**Koral H see Hammill K**
**Kraus RP:** Postpartum anxiety disorder (letter with reply). July 268
**Kruesi MJP, Dale J, Straus SE:** Psychiatric diagnoses in patients who have chronic fatigue syndrome. Feb 53–56. Correction, Apr 148
**Kuhn LF:** Review of Bernstein NR, Breslau AJ, Graham JA (eds): *Coping Strategies for Burn Survivors and Their Families.* Nov 439
**Kupfer DJ, Perel JM, Frank E:** Adequate treatment with imipramine in continuation treatment. July 250–255
**Kupfer DJ see Lahmeyer HW; Thase ME; Thase ME**
**Lahmeyer HW, Reynolds CF III, Kupfer DJ, King R:** Biologic markers in borderline personality disorder: A review. June 217–225
**Laird LK, Lydiard RB:** Imipramine-related tinnitus (letter). Apr 146
**Landa BS see Pandurangi AK**
**Langlow JR, Alarcon RD:** Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. Apr 144–145
**Larocca FEF:** Review of Altschul AM (ed): *Weight Control: A Guide for Counselors and Therapists.* Jan 38–39
**Larocca FEF:** Review of Reid WH: *The Treatment of Psychiatric Disorders: Revised for the DSM-III-R.* Oct 395
**Larocca FEF:** Review of Roccatagliata G: *A History of Ancient Psychiatry.* Feb 75
**Larocca FEF:** Review of Stierlin H, Weber G: *Unlocking the Family Door: A Systemic Approach to the Understanding and Treatment of Anorexia Nervosa.* Nov 439
**Larocca FEF:** Review of Walsh BT (ed): *Eating Behaviors in Eating Disorders.* Sept 361
**Lazarus A, Cotterell KP:** SPECT scan reveals abnormality in somatization disorder patient (letter). Dec 475–476
**Lee S, Wing YK, Chow CC, Chung S, Yung C:** Gastric outlet obstruction masquerading as anorexia nervosa. May 184–185
**Leon-Andrade C:** Review of Freedman DX, Lourie RS, Meltzer HY, Talbott JA, Weiner H (eds): *1988: The Year Book of Psychiatry and Applied Mental Health.* Mar 112
**Levenson JL:** Treatable causes of CNS dysfunction in AIDS patients (letter with reply). Apr 147–148
**Levine SB:** Review of Friedman RC: *Male Homosexuality: A Contemporary Psychoanalytic Perspective.* Apr 149
**Levy AB, Luzny J:** Inability to predict postdexamethasone cortisol levels by serum sodium levels. Jan 16–17
**Levy JK see Holmes VF**
**Lieberman JA, Kane JM, Johns CA:** Clozapine: Guidelines for clinical management. Sept 329–338
**Liebowitz MR:** MAOIs in DST nonsuppressors (letter with reply). Mar 107
**Links PS:** Review of Katschnig H (ed): *Life Events and Psychiatric Disorders: Controversial Issues.* Aug 312
**Linnoila MI:** Anxiety and alcoholism. Nov Suppl 26–29
**Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr:** Fluoxetine-induced akathisia: Clinical and theoretical implications. Sept 339–342
**Liston EH see Guze BH**
**Londong V see Wolf B**
**Long CJ see Ross L**
**Lutherer L see Spring B**
**Luzny J see Levy AB**
**Lydiard RB:** Buspirone revisited (letter). Aug 308
**Lydiard RB see Laird LK**
**Mallya G see Lipinski JF Jr**
**Manschreck TC see Garber HJ**
**Martin CA see Burton KR**
**Mason JD see Spring B**
**Mattes JA:** Clozapine for refractory schizophrenia: An open study of 14 patients treated up to 2 years. Oct 389–391
**Mavissakalian M:** Review of Rachman S, Maser J: *Panic: Psychological Perspectives.* May 189
**McCall WV:** Neuroendocrine markers in periodic catatonia (letter). Mar 109
**McCall WV see McGough JJ**
**McClain CJ see Humphries L**
**McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI:** Valproate in psychiatric disorders: Literature review and clinical guidelines. Mar Suppl 23–29
**McElroy SL see Keck PE Jr**
**McEvoy JP see Hammill K**
**McGough JJ, McCall WV, Shelp FE:** ECT in children and adolescents (letter with reply) Mar 106
**McGrath PJ see Harrison WM**
**McMillan DE see Newton JEO**
**McNamara ME see Millman RP**
**Metz A, Goff DC, Sichel DA:** Replies to Kraus RP; Bybee P; Fisch RZ: Postpartum anxiety disorder (letters). July 269
**Metzer WS see Newton JEO**
**Meyer RE:** Prospects for a rational pharmacotherapy of alcoholism (Festschrift). Nov 403–412
**Mikkelsen E see Ratey JJ**
**Miller FT see Busch FN**
**Miller H see Golden RN**
**Miller MB:** Hallervorden-Spatz disease (letter with reply). Aug 309
**Millman RP, Fogel BS, McNamara ME, Carlisle CC:** Depression as a manifestation of obstructive sleep apnea: Reversal with nasal continuous positive airway pressure. Sept 348–351
**Mirin SM see Weiss RD**
**Molcho A see Hermesh H**
**Morphy MA, Feldman JA, Kilburn G:** Hallervorden-Spatz disease in a psychiatric setting. Feb 66–68
**Morphy MA, Feldman JA, Kilburn G:** Reply to Miller MB: Hallervorden-Spatz disease (letter). Aug 309
**Mukherjee D see Eapen V**
**Munitz H see Hermesh H; Shalev A; Shalev A**
**Muniz CE see Burton KR**
**Muñoz RA:** Review of Boaz JT: *Delivering Mental Health Care: A Guide for HMOs.* Mar 110
**Murray FT see Burton KR**
**Musa MN:** Dose-dependent kinetics of trimipramine (letter). Aug 307
**Narasimhachari N see Pandurangi AK**
**Nasrallah HA:** Review of Theodore WH (ed): *Clinical Neuroimaging.* Mar 110
**Nee J see Harrison WM**
**Nelson JC see Satel SL**
**Nemeroff CB:** Clinical significance of psychoneuroendocrinology in psychiatry: Focus on the thyroid and adrenal. May Suppl 13–20
**Newton JEO, Cannon DJ, Couch L, Fody EP, McMillan DE, Metzer WS, Paige SR, Reid GM, Summers BN:** Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. Apr 132–135
**Neylan TC, Reynolds CF III:** Review of Mendelson WB: *Human Sleep: Research and Clinical Care.* Oct 394–395
**Noyes R Jr, Garvey MJ, Cook BL, Samuelson L:** Problems with tricyclic use in patients with panic disorder or agoraphobia: Results of a naturalistic follow-up study. May 163–169
**Noyes R Jr see Reich J**
**Nunes E, Quitkin F:** Reply to Burant DM: Coexisting panic disorder and alcoholism (letter). May 188
**O'Donnell V see Coffman JA**
**O'Rourke D, Wurtman JJ, Wurtman RJ, Chebli R, Gleason R:** Treatment of seasonal depression with *d*-fenfluramine. Sept 343–347
**Olson SC see Coffman JA**
**Ostrow DG, Grant I, Atkinson H:** Reply to Levenson JL: Treatable causes of CNS dysfunction in AIDS patients (letter). Apr 148
**Paige SR see Newton JEO**
**Pal GS:** Review of Moffic HS, Silverman SW, Adams GL (eds): *Psychiatry: A Problem-Oriented Approach.* Mar 111
**Pallanti S:** Review of Guidano V: *Complexity of the Self: A Developmental Approach to Psychopathology and Therapy.* Aug 313
**Pandurangi AK, Narasimhachari N, Blackard WG, Landa BS:** Relation of serum molindone levels to serum prolactin levels and antipsychotic response. Oct 379–381
**Pasley DR see Resnick MP**
**Pasnau RO:** Introduction. Anxiety: The silent partner. Nov Suppl 3–4
**Pawel BR, Kaye WA, Khan MY, Fergusen BD, Federman M, Crosson AW:** Aggravation of diabetic nephropathy by lithium: A case report and review of the literature. Mar 101–103
**Penry JK, Dean JC:** Scope and use of valproate in epilepsy. Mar Suppl 17–22
**Peppie JR, Tsuang MT:** Review of Schepank H: *Epidemiology of Psychogenic disorders: The Mannheim Study: Results of a Field Survey in the Federal Republic of Germany.* May 190
**Perel JM see Kupfer DJ**
**Perry PJ, Garvey MJ, Kelly MW, Cook BL, Dunner FJ, Winokur G:** A comparative trial of fluoxetine versus trazodone in outpatients with major depression. Aug 290–294
**Peselow E see Reiter S**
**Piper A Jr:** Tricyclics: Adequate trials and plasma levels (letter with reply). Jan 36
**Pitman RK, Jenike MA:** Normal and disordered compulsivity: Evidence against a continuum. Dec 450–452
**Pohl R, Yeragani VK, Balon R:** Reply to Ciccone PE: Jitteriness and panic disorder (letter). Feb 72–73
**Pohl R see Kim C-L**
**Pollack MH see Weilburg JB**
**Pope HG Jr see Keck PE Jr; Lipinski JF Jr; McElroy SL**
**Popkin MK see Colón EA**
**Porter RJ see Devinsky O**
**Post RM:** Introduction: Emerging perspectives on valproate in affective disorders. Mar Suppl 3–9
**Post RM, Weiss SRB:** Sensitization, kindling, and anticonvulsants in mania. Dec Suppl 23–30
**Preskorn SH:** Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. July Suppl 34–42
**Price LH, Goodman WK:** Obsessive compulsive disorder (letter). June 232
**Quitkin F see Harrison WM; Nunes E**
**Rabe RH:** Anxiety and coronary heart disease in midlife. Nov Suppl 36–39
**Rajadhyaksha R:** Avoidant personality traits in social phobic patients treated with alprazolam (letter with reply). Nov 437
**Rasmussen SA see Eisen JL**
**Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE:** Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. Oct 382–384
**Rego MD, Giller EL Jr:** Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. Apr 143–144
**Reich JH:** Reply to Rajadhyaksha S: Avoidant personality traits in social phobic patients treated with alprazolam (letter). Nov 437
**Reich J, Noyes R Jr, Yates W:** Alprazolam treatment of avoidant personality traits in social phobic patients. Mar 91–95
**Reich J see Yates WR**
**Reid GM see Newton JEO**

**Reiter S, Adler L, Angrist B, Peselow E, Rotrosen J:** Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. Jan 26–27
**Resnick MP, Pasley DR, Siemsen FK, Yok L:** Nicotine gum use with nicotine addiction (letter). Aug 310
**Restak RM:** Brain, depression, and the immune system. May Suppl 23–25
**Reynolds CF III see Lahmeyer HW; Neylan TC**
**Rice SN:** Review of Klarreich SH (ed): *Health and Fitness in the Workplace: Health Education in Business Organizations.* Mar 111
**Richelmer SH see Guze BH**
**Rihmer Z, Gombos I, Hada Z, Gyorgy S, Arato M:** Dexamethasone suppression test and response to MAOI treatment (letter). Mar 107–108
**Rinsley DB:** Review of Schneiderman L: *The Literary Mind: Portraits in Pain and Creativity.* Apr 150
**Rinsley DB:** Review of Editorial Committee of the Chicago Institute for Psychoanalysis: *The Annual Review of Psychoanalysis, Vol. 15.* Jan 39
**Robinson RG see Fedoroff JP**
**Rodin GM see Kennedy SH**
**Roose SP, Glassman AH, Dalack GW:** Depression, heart disease, and tricyclic antidepressants. July Suppl 12–16
**Rorty M see Bulik CM**
**Rosebush PI, Stewart TD, Gelenberg AJ:** Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients, Aug 295–298. Correction, Dec 472
**Rosen A see Fox HA**
**Rosenbaum JF:** Introduction. Mania: Important New Findings. Dec Suppl 3
**Rosenbaum JF:** Summary. Dec Suppl 45–47
**Rosenbaum JF see Cohen LS; Weilburg JB**
**Rosenbluth M:** Review of Green SA, Goldberg RL, Goldstein DM, Leibenluft E: *Limit Setting in Clinical Practice.* July 271
**Rosenthal NE, DellaBella P, Hahn L, Skwerer RG:** Seasonal affective disorder and visual impairment: Two case studies. Dec 469–471
**Rosenthal TL see Downs JM**
**Ross L, Long CJ:** Review of Berg R, Franzen M, Wedding D: *Screening for Brain Impairment: A Manual for Mental Health Practice.* May 189–190
**Roth M:** Anxiety disorders and the use and abuse of drugs. Nov Suppl 30–35
**Rotrosen J see Reiter S**
**Roy-Byrne PP, Ward NG, Donnelly PJ:** Valproate in anxiety and withdrawal syndromes. Mar Suppl 44–48
**Roy-Byrne PP see Katon W**
**Rüther E see Wolf B**
**Sachs GS:** Adjuncts and alternatives to lithium therapy for bipolar affective disorder. Dec Suppl 31–39
**Sachs GS, Gelenberg AJ, Bellinghausen B, Wojcik J, Falk WE, Farhadi AM, Jenike M:** Ergoloid mesylates and ECT. Mar 87–90
**Sachs GS see Weilburg JB**
**Sajatovic M see Fuller MA**
**Samuelson L see Noyes R Jr**
**Santos AB see Arana GW**
**Satel SL, Nelson JC:** Stimulants in the treatment of depression: A critical overview. July 241–249
**Sato S see Devinsky O**
**Saxon AJ, Whittaker S, Hawker CS:** Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: Two cases. June 228–229
**Schmid LS:** Review of Chess S, Thomas A, Hertzig M (eds): *Annual Progress in Child Psychiatry and Child Development: 1987.* Sept 359
**Schneck JM:** Reply to Wright AJ: More on cocaine addiction and Dr. William S. Halsted (letter). Sept 358
**Schneck JM:** Separation anxiety and fear or avoidance of flying (letter). Dec 474
**Schneider N see Hammill K**
**Schoorlemmer GHM see Kemperman CJF**
**Schuyler D:** Review of Luborsky L, Crits-Christoph P, Mintz J, Auerbach A: *Who Will Benefit From Psychotherapy? Predicting Therapeutic Outcomes.* Sept 360–361
**Sebastianelli J see Keck PE Jr**
**Shalev A, Hermesh H, Munitz H:** Mortality from neuroleptic malignant syndrome. Jan 18–25
**Shalev A, Hermesh H, Munitz H, Birger M:** Chlorprothixene-induced hypouricemia: A biologic indicator of drug compliance. Nov 424–427
**Sharma RP see Janicak PG**
**Shelp FE see McGough JJ**
**Shukla S see Aronson TA**
**Sichel DA see Metz A**
**Sieleni B see Yates WR**
**Siemsen FK see Resnick MP**
**Sierles FS see Jampala VC**
**Simpson GM:** Reply to Boyer WF, Feighner JP: Plasma trimipramine levels (letter). Mar 108–109
**Sinha V see Eapen V**
**Skwerer RG see Rosenthal NE**
**Small GW:** Tricyclic antidepressants for medically ill geriatric patients. July Suppl 27–31
**Smeltzer DJ see Coffman JA**
**Solan WJ see Khan A; Khan A**
**Sovner R:** Use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. Mar Suppl 40–43
**Sovner R see Ratey JJ**
**Spring B, Chiodo J, Harden M, Bourgeois MJ, Mason JD, Lutherer L:** Psychobiological effects of carbohydrates. May Suppl 27–33
**Stein M:** Stress, depression, and the immune system. May Suppl 35–40
**Stewart JT:** Reply to von Hafften AH, Jensen CF: Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease (letter). June 230–231
**Stewart JW see Harrison WM**
**Stewart TD see Rosebush PI**
**Strassman RJ:** Review of Nace EP: *The Treatment of Alcoholism.* Feb 74–75
**Straus SE see Kruesi MJP**
**Strauss A:** Homicidal psychosis during the combined use of cocaine and an over-the-counter cold preparation (letter). Apr 147
**Stuart M see Humphries L**
**Sullivan PF see Bulik CM**
**Summers BN see Newton JEO**
**Sundar SK see Weiss JM**
**Surawicz FG:** Review of Bachrach LL, Nadelson CC (eds): *Treating Chronically Mentally Ill Women.* Mar 112
**Surawicz FG:** Review of Blatner A, Blatner A: *Foundations of Psychodrama: History, Theory and Practice.* June 234
**Surawicz FG:** Review of Rothblum ED, Cole E (eds): *Treating Women's Fear of Failure.* Sept 361
**Tandon R see DeQuardo JR**
**Taylor MA see Atre-Vaidya N; Jampala VC**
**Terr LC:** Family anxiety after traumatic events. Nov Suppl 15–19
**Thaggard SL:** Review of Ablon J: *Living With Difference: Families With Dwarf Children.* Dec 478
**Thase ME, Kupfer DJ, Frank E, Jarrett DB:** Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. Nov 413–417
**Thase ME, Kupfer DJ, Jarrett DB:** Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. Oct 385–388
**Theodore WH see Devinsky O**
**Thompson-Pope SK, Turkat ID:** Paranoia about paranoid personality research (letter). Aug 310
**Thweatt R:** Obsessive compulsive disorder (letter). June 232
**Tobin D see Johnson C**
**Toledo L:** Review of Selvini M (ed): *The Work of Mara Selvini Palazzoli.* Aug 311
**Tsuang MT see Pepple JR**
**Turkat ID see Thompson-Pope SK**
**Turnbull JM:** Anxiety and physical illness in the elderly. Nov Suppl 40–45
**Unck F see van Bavel LP**
**van Bavel LP, van Hoof JJM, Unck F, Bouwens JMP:** Delusions in Marfan's syndrome (letter). Dec 473–474
**van den Hoofdakker R see Kemperman CJF**
**van Hoof JJM see van Bavel LP**
**Vivian B see Humphries L**
**von Hafften AH, Jensen CF:** Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease (letter with reply). June 230
**Walden M see Alessi NE**
**Walker PW:** Review of Diamond S: *Hope for Your Headache Problem.* June 234
**Walker PW:** Review of Liberman RP (ed): *Psychiatric Rehabilitation of Chronic Mental Patients.* Feb 75
**Ward NG see Roy-Byrne PP**
**Warneke LB:** Obsessive compulsive disorder (letter). June 232
**Wazirl R:** Review of Gooddy W: *Time and the Nervous System.* Nov 438–439
**Wehr TA:** Sleep loss: A preventable cause of mania and other excited states. Dec Suppl 8–16
**Weiden PJ see Busch FN**
**Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K:** Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. Dec 447–449
**Weilburg JB see Garber HJ**
**Weiss JM, Sundar SK, Becker KJ, Cierpial MA:** Behavioral and neural influences on cellular immune responses: Effects of stress and interleukin-1. May Suppl 43–53
**Weiss RD, Mirin SM:** Tricyclic antidepressants in the treatment of alcoholism and drug abuse. July Suppl 4–8
**Weiss SRB see Post RM**
**Weller EB, Fristad MA:** Review of Benson HB: *The Dying Child: An Annotated Bibliography.* June 233
**Westermeyer J:** Case of koro in a refugee family: Association with depression and folie à deux. May 181–183
**White K see Bodkin JA**
**Whittaker S see Saxon AJ**
**Wing YK see Lee S**
**Winokur G see Black DW; Perry PJ**
**Witzgall H see Wolf B**
**Witztum E see Daie N**
**Wojcik JD see Gelenberg AJ**
**Wojcik J see Sachs GS**
**Wolf B, Conradty M, Grohmann R, Rüther E, Witzgall H, Londong V:** Case of immune complex hemolytic anemia, thrombocytopenia, and acute renal failure associated with doxepin use. Mar 99–100
**Woods SW see Charney DS**
**Wright AJ:** More on cocaine addiction and Dr. William S. Halsted (letter with reply). Sept 358
**Wurtman JJ see O'Rourke D**
**Wurtman RJ see O'Rourke D**
**Yates W see Reich J**
**Yates WR, Sieleni B, Reich J, Brass C:** Comorbidity of bulimia nervosa and personality disorder. Feb 57–59
**Yeragani VK see Kim C-L; Pohl R**
**Yerevanian B see Gupta BK**
**Yok L see Resnick MP**
**Yung C see Lee S**
**Zimmerman P see Lipinski JF Jr**